Literature DB >> 10089162

Analysis of the Yersinia enterocolitica 0:8 V antigen for cross protectivity.

A Schmidt1, S Schaffelhofer, K Müller, M Röllinghoff, H U Beuscher.   

Abstract

The plasmid encoded V antigen (Vag) of pathogenic Yersinia spp. is a major virulence factor as well as a protective immunogen. Recently, two main types of Vag, represented by either Yersinia enterocolitica 0:8 or Yersinia pseudotuberculosis, have been identified and it has been suggested, that antibodies generated against one type are unable to protect against Yersinia spp. carrying the other type. By using a recombinant Vag (rVagHis) of the Y. enterocolitica 0:8 type we show here, that actively immunized mice were completely protected against challenge with both, Y. enterocolitica 0:8 and Y. pseudotuberculosis serotype III. In addition, passive protection was possible with polyclonal rabbit anti-rVagHisIgG. However, while a single antibody dose (200 microgramg) was sufficient to protect against challenge with Y. enterocolitica 0:8, repetitive injections at intervals of 2 to 3 days were needed to protect against challenge with Y. pseudotuberculosis III. The apparent difference in protection correlated with a rapid disappearance of anti-rVagHisIgG from the circulation by days 3 to 4. The data therefore indicate, that expression of distinct types of Vag by Yersinia spp. does not necessarily exclude immunoprotection in mice immunized with the other type of Vag. It rather appears, that differences in immunoprotection between Yersinia species relate to the amount of cross-protective antibody. Finally, as revealed by the lack of complement-mediated killing and the lack of immunostaining of Yersiniae with anti-rVagHisantibodies, evidence is provided to indicate that immunoprotection does not occur via opsonisation or complement lysis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10089162     DOI: 10.1006/mpat.1998.0268

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  4 in total

1.  Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy.

Authors:  Susan V Lynch; Judith L Flanagan; Teiji Sawa; Alice Fang; Marshall S Baek; Amua Rubio-Mills; Temitayo Ajayi; Katsunori Yanagihara; Yoichi Hirakata; Shigeru Kohno; Benoit Misset; Jean-Claude Nguyen; Jeanine P Wiener-Kronish
Journal:  Microb Pathog       Date:  2010-03-06       Impact factor: 3.738

2.  A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice.

Authors:  Shannon J Heine; Olga L Franco-Mahecha; Khandra T Sears; Cinthia B Drachenberg; Maarten L van Roosmalen; Kees Leenhouts; Wendy L Picking; Marcela F Pasetti
Journal:  J Immunol       Date:  2019-02-20       Impact factor: 5.422

3.  Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.

Authors:  Christine G Branger; Ascención Torres-Escobar; Wei Sun; Robert Perry; Jacqueline Fetherston; Kenneth L Roland; Roy Curtiss
Journal:  Vaccine       Date:  2009-07-09       Impact factor: 3.641

4.  Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model.

Authors:  Catherine Daniel; Amélie Dewitte; Sabine Poiret; Michaël Marceau; Michel Simonet; Laure Marceau; Guillaume Descombes; Denise Boutillier; Nadia Bennaceur; Sébastien Bontemps-Gallo; Nadine Lemaître; Florent Sebbane
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.